دورية أكاديمية
أعرض في EDS

Dysregulated Polycomb Repressive Complex 2 contributes to chronic obstructive pulmonary disease by rewiring stem cell fate.

التفاصيل البيبلوغرافية
العنوان: Dysregulated Polycomb Repressive Complex 2 contributes to chronic obstructive pulmonary disease by rewiring stem cell fate.
المؤلفون: Byrd AL; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Qu X; Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA., Lukyanchuk A; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Liu J; Department of Internal Medicine, University of Kentucky, Lexington, KY, USA., Chen F; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Naughton KJ; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., DuCote TJ; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Song X; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Bowman HC; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Zhao Y; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Edgin AR; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA., Wang C; Department of Internal Medicine, University of Kentucky, Lexington, KY, USA; Markey Cancer Center, University of Kentucky, Lexington, KY, USA., Liu J; Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA., Brainson CF; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA; Markey Cancer Center, University of Kentucky, Lexington, KY, USA. Electronic address: cfbrainson@uky.edu.
المصدر: Stem cell reports [Stem Cell Reports] 2023 Jan 10; Vol. 18 (1), pp. 289-304. Date of Electronic Publication: 2022 Dec 15.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101611300 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-6711 (Electronic) Linking ISSN: 22136711 NLM ISO Abbreviation: Stem Cell Reports Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, c 2013-
مواضيع طبية MeSH: Polycomb Repressive Complex 2*/genetics , Pulmonary Disease, Chronic Obstructive*/genetics, Humans ; Mice ; Animals ; Cell Differentiation/genetics ; Enhancer of Zeste Homolog 2 Protein/genetics ; Embryonic Stem Cells ; Polycomb Repressive Complex 1
مستخلص: Aberrant lung cell differentiation is a hallmark of many lung diseases including chronic obstructive pulmonary disease (COPD). The EZH2-containing Polycomb Repressive Complex 2 (PRC2) regulates embryonic lung stem cell fate, but its role in adult lung is obscure. Histological analysis of patient tissues revealed that loss of PRC2 activity was correlated with aberrant bronchiolar cell differentiation in COPD lung. Histological and single-cell RNA-sequencing analyses showed that loss of EZH2 in mouse lung organoids led to lowered self-renewal capability, increased squamous morphological development, and marked shifts in progenitor cell populations. Evaluation of in vivo models revealed that heterozygosity of Ezh2 in mice with ovalbumin-induced lung inflammation led to epithelial cell differentiation patterns similar to those in COPD lung. We also identified cystathionine-β-synthase as a possible upstream factor for PRC2 destabilization. Our findings suggest that PRC2 is integral to facilitating proper lung stem cell differentiation in humans and mice.
Competing Interests: Conflict of interests The authors declare no competing interests.
(Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
References: Nat Commun. 2017 Jun 09;8:15901. (PMID: 28598439)
Cell Stem Cell. 2009 Jun 5;4(6):525-34. (PMID: 19497281)
Lung Cancer. 2015 Nov;90(2):121-7. (PMID: 26363803)
Cell Stem Cell. 2020 Sep 3;27(3):366-382.e7. (PMID: 32750316)
Clin Lung Cancer. 2021 Nov;22(6):e911-e920. (PMID: 33958300)
Science. 2004 Jan 16;303(5656):359-63. (PMID: 14671312)
J Biol Chem. 2003 Aug 1;278(31):29336-43. (PMID: 12732635)
Nat Rev Cancer. 2009 Nov;9(11):773-84. (PMID: 19851313)
Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L888-900. (PMID: 19286929)
Nat Cell Biol. 2020 Aug;22(8):934-946. (PMID: 32661339)
Thorax. 2017 Dec;72(12):1074-1083. (PMID: 28724639)
Sci Adv. 2020 Jul 08;6(28):eaba1983. (PMID: 32832599)
Cancer Cell. 2016 Jan 11;29(1):17-31. (PMID: 26766588)
Expert Opin Drug Discov. 2014 Jun;9(6):609-28. (PMID: 24850530)
Nat Commun. 2020 Jul 16;11(1):3559. (PMID: 32678092)
Sci Rep. 2015 Feb 02;5:8163. (PMID: 25641363)
Am J Respir Cell Mol Biol. 2004 Oct;31(4):382-94. (PMID: 15191915)
Mol Cell. 2008 Nov 21;32(4):491-502. (PMID: 19026780)
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10482-7. (PMID: 12145322)
J Allergy Clin Immunol. 2013 Mar;131(3):752-62. (PMID: 23380220)
Nat Cancer. 2021 Sep;2(9):919-931. (PMID: 34917944)
Thorax. 2004 Aug;59(8):679-81. (PMID: 15282388)
Genome Med. 2015 Feb 14;7(1):12. (PMID: 25763110)
Proc Am Thorac Soc. 2006 Nov;3(8):718-25. (PMID: 17065380)
Cell. 2005 May 6;121(3):465-77. (PMID: 15882627)
EMBO Rep. 2021 Aug 4;22(8):e52785. (PMID: 34224201)
Sci Adv. 2020 Jul 08;6(28):eaba1972. (PMID: 32832598)
Am J Respir Cell Mol Biol. 2017 Jul;57(1):3-4. (PMID: 28665224)
JCI Insight. 2019 May 16;4(10):. (PMID: 31092733)
Biomed Res Int. 2018 Jun 28;2018:3205125. (PMID: 30050925)
Cell Host Microbe. 2014 Jun 11;15(6):753-67. (PMID: 24922577)
Cancer Res. 2004 Dec 15;64(24):9027-34. (PMID: 15604268)
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1355-62. (PMID: 25354273)
Nature. 2018 Aug;560(7717):238-242. (PMID: 30046113)
Mucosal Immunol. 2014 Mar;7(2):215-26. (PMID: 24150257)
J Clin Invest. 2013 Sep;123(9):3967-82. (PMID: 23945235)
Am J Respir Cell Mol Biol. 2004 Dec;31(6):601-10. (PMID: 15374838)
Development. 2007 May;134(10):1991-2000. (PMID: 17428829)
Development. 2015 Jan 1;142(1):108-17. (PMID: 25516972)
Proc Am Thorac Soc. 2006 Aug;3(6):535-7. (PMID: 16921139)
Lancet. 2011 Sep 10;378(9795):1015-26. (PMID: 21907865)
J Proteome Res. 2014 Feb 7;13(2):982-96. (PMID: 24283195)
Sci Rep. 2019 Oct 30;9(1):15682. (PMID: 31666665)
EMBO J. 2016 Nov 2;35(21):2301-2314. (PMID: 27585866)
Development. 2015 Apr 15;142(8):1458-69. (PMID: 25790853)
معلومات مُعتمدة: P20 GM121327 United States GM NIGMS NIH HHS; T32 ES007266 United States ES NIEHS NIH HHS; R01 CA237643 United States CA NCI NIH HHS; P30 CA177558 United States CA NCI NIH HHS; K22 CA201036 United States CA NCI NIH HHS; F31 HL151111 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: Polycomb Repressive Complex; chronic obstructive pulmonary disease; lung stem cells; organoids
المشرفين على المادة: EC 2.1.1.43 (Polycomb Repressive Complex 2)
EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
EC 2.3.2.27 (Polycomb Repressive Complex 1)
تواريخ الأحداث: Date Created: 20221216 Date Completed: 20230113 Latest Revision: 20230331
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9860081
DOI: 10.1016/j.stemcr.2022.11.009
PMID: 36525966
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-6711
DOI:10.1016/j.stemcr.2022.11.009